Back to Treatments

Treatment

Ixekizumab

2
Conditions
56
Trials
23K
Participants
59%
Average Safety

Condition Evidence

Ankylosing Spondylitis

8 trials · 8,000 participants

69% effectiveness · 60% safety

Psoriasis

48 trials · 15K participants

90% effectiveness · 58% safety
Ixekizumab | DFDA